Lord, Abbett & Co
ELVN icon

Lord, Abbett & Co’s Enliven Therapeutics ELVN Stock Holding History

Lord, Abbett & Co’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.8M Buy
+330,759
New +$14M 0.05% 321
2025
Q2 		– Sell
-197,279
Closed -$3.88M – 534
2025
Q1 		$3.88M Sell
197,279
-188,932
-49% -$4.07M 0.01% 479
2024
Q4 		$8.69M Buy
386,211
+65,156
+20% +$1.69M 0.03% 401
2024
Q3 		$8.2M Buy
+321,055
New +$7.44M 0.03% 419

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Lord, Abbett & Co's ELVN Position: Q2 2026 in Review

Lord, Abbett & Co opened a new position in Enliven Therapeutics (ELVN) in Q2 2026: 330,759 shares worth $16.8M. The stake represents 0.05% of the portfolio and ranks #321 among its holdings. This is a return to the name: Lord, Abbett & Co previously reported a position in ELVN as recently as Q1 2025.

Lord, Abbett & Co first reported a position in ELVN in Q3 2024 and has held it in 4 quarters since. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Lord, Abbett & Co held 330,759 shares of Enliven Therapeutics worth $16.8M as of Q2 2026.
  • Enliven Therapeutics was a new Lord, Abbett & Co position in Q2 2026.
  • Enliven Therapeutics made up 0.05% of Lord, Abbett & Co's portfolio in Q2 2026, its #321 holding.
  • Lord, Abbett & Co first reported a position in Enliven Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Lord, Abbett & Co's 13F filing for Q2 2026, filed 14 Aug 2026.